Inherited Retinal Diseases (IRDs) are a heterogeneous group of genetically based degenerative retinal disorders, representing a major cause of visual impairment and blindness in working-age adults. Despite the approval of the first gene therapy for RPE65-related IRD (voretigene neparvovec) in 2017, most IRDs remain untreatable, though many gene therapies are in development. Effective trial design and therapy development require a deep understanding of disease natural history and genotype-phenotype correlations. Over 270 IRD-associated genes are known (e.g., ABCA4, USH2A, RPGR, PRPH2, BEST1), each linked to distinct phenotypes and clinical progression. This retrospective study analyzes clinical, functional, and imaging data (Optical Coherence Tomography, Fundus Autofluorescence, Microperimetry) from a large, genetically characterized IRD cohort at the IRCCS Ospedale San Raffaele up to December 31, 2025. The aims are to describe natural history, define genotype-phenotype relationships, and identify structural and functional outcome measures useful for future clinical trial endpoints, supporting personalized prognosis and trial design.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Best-corrected Visual Acuity
Timeframe: through study completion, an average of 1 year
Macular threshold sensitivity
Timeframe: through study completion, an average of 1 year
Total Macular volume
Timeframe: through study completion, an average of 1 year
Centra Subfield Thickness
Timeframe: through study completion, an average of 1 year
Preserved Ellipsoid zone area
Timeframe: through study completion, an average of 1 year
Foveal Outer Nuclear Layer thickness
Timeframe: through study completion, an average of 1 year
Ellipsoid zone loss area
Timeframe: through study completion, an average of 1 year
Hyperautofluorescent (Robson- Holder) ring area
Timeframe: through study completion, an average of 1 year
Dereased Autofluorescence area
Timeframe: through study completion, an average of 1 year